Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Nutr ; 143(2): 142-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23236022

ABSTRACT

Plasma vitamin B-12 is the most commonly used biomarker of vitamin B-12 status, but the predictive value for low vitamin B-12 status is poor. The urinary methylmalonic acid (uMMA) concentration has potential as a functional biomarker of vitamin B-12 status, but the response to supplemental vitamin B-12 is uncertain. A study was conducted to investigate the responsiveness of uMMA to supplemental vitamin B-12 in comparison with other biomarkers of vitamin B-12 status [plasma vitamin B-12, serum holotranscobalamin (holoTC), plasma MMA] in elderly people with moderately poor vitamin B-12 status. A double-blind, placebo-controlled, randomized 8-wk intervention study was carried out using vitamin B-12 supplements (500 µg/d, 100 µg/d, and 10 µg/d cyanocobalamin) in 100 elderly people with a combined plasma vitamin B-12 <250 pmol/L and uMMA ratio (µmol MMA/mmol creatinine) >1.5. All biomarkers had a dose response to supplemental vitamin B-12. Improvements in plasma vitamin B-12 and serum holoTC were achieved at cobalamin supplements of 10 µg/d, but even 500 µg/d for 8 wk did not normalize plasma vitamin B-12 in 8% and serum holoTC in 12% of people. The response in uMMA was comparable with plasma MMA; 15-25% of people still showed evidence of metabolic deficiency after 500 µg/d cobalamin for 8 wk. There was a differential response in urinary and plasma MMA according to smoking behavior; the response was enhanced in ex-smokers compared with never-smokers. uMMA offers an alternative marker of metabolic vitamin-B12 status, obviating the need for blood sampling.


Subject(s)
Aging , Dietary Supplements , Methylmalonic Acid/urine , Nutritional Status , Vitamin B 12 Deficiency/diet therapy , Vitamin B 12/administration & dosage , Aged , Aged, 80 and over , Apoproteins/blood , Biomarkers/blood , Biomarkers/urine , Creatinine/urine , Cross-Sectional Studies , Double-Blind Method , Female , Humans , Male , Methylmalonic Acid/blood , Patient Compliance , Smoking/adverse effects , Time Factors , Transcobalamins/analysis , Vitamin B 12/blood , Vitamin B 12/therapeutic use , Vitamin B 12 Deficiency/blood , Vitamin B 12 Deficiency/physiopathology , Vitamin B 12 Deficiency/urine
2.
Am J Clin Nutr ; 95(3): 686-93, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22301932

ABSTRACT

BACKGROUND: An age-related deterioration of vitamin B-12 status has been well documented. The early detection of deficiency may prevent the development of serious clinical symptoms, but plasma vitamin B-12 concentration is known to be an imperfect measure of vitamin B-12 status. Urinary methylmalonic acid (MMA) may be a more informative biomarker of vitamin B-12 status; however, biochemical, dietary, and other lifestyle determinants are not known. OBJECTIVE: We identified determinants of urinary MMA concentrations in free-living men and women aged ≥65 y in the United Kingdom. DESIGN: A cross-sectional study in 591 men and women aged 65-85 y, with no clinical evidence of vitamin B-12 deficiency, was conducted to determine the demographic, clinical, and lifestyle determinants of urinary MMA concentration expressed as the ratio of micromoles of MMA to millimoles of creatinine (uMMA ratio). RESULTS: Twenty percent of subjects had plasma vitamin B-12 concentrations <200 pmol/L. Seventeen percent of the variation in the uMMA ratio could be explained by plasma holotranscobalamin and sex; total vitamin B-12 intake and measures of renal function and gastric function made only a small contribution to the model. The uMMA ratio was lower in people with moderately impaired renal function. CONCLUSIONS: Plasma holotranscobalamin and sex were the most important determinants of uMMA ratio in elderly people with no clinical diagnosis of renal impairment. This biomarker might underestimate vitamin B-12 deficiency in a population in which renal impairment is prevalent. This trial was registered at www.controlled-trials.com as ISRCJN83921062.


Subject(s)
Methylmalonic Acid/urine , Vitamin B 12 Deficiency/diagnosis , Vitamin B 12 Deficiency/epidemiology , Aged , Aged, 80 and over , Biomarkers/urine , Cross-Sectional Studies , Female , Humans , Life Style , Male , Prevalence , Randomized Controlled Trials as Topic , Transcobalamins/analysis , United Kingdom/epidemiology , Vitamin B 12/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...